Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | DRD4 | P21917 | 8/20 | 0.47 |
| ▸ | DRD3 | P35462 | 8/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395238 | 0.80 | DRD2 (0.49) | DRD2DRD4DRD3HRH3ACHE | |
| SCHEMBL4388965 | 0.78 | DRD2 (0.47) | DRD2DRD4DRD3HRH3ACHE | |
| SCHEMBL4386020 | 0.70 | DRD2 (0.47) | DRD2DRD4DRD3HRH3ACHE | |
| SCHEMBL4382962 | 0.68 | HRH3 (0.54) | DRD2DRD4DRD3HRH3MEN1 | |
| SCHEMBL4384577 | 0.68 | DRD2 (0.45) | DRD2DRD4DRD3HRH3ACHE | |
| SCHEMBL311417 | 0.66 | ACHE (0.61) | DRD2DRD4DRD3HRH3ACHE | |
| SCHEMBL9311969 | 0.65 | HTR2A (0.50) | DRD2DRD4DRD3ACHECCR3 | |
| SCHEMBL9311974 | 0.65 | HTR2A (0.50) | DRD2DRD4DRD3ACHECCR3 | |
| SCHEMBL1206639 | 0.65 | SIGMAR1 (0.69) | DRD2DRD4DRD3ACHESIGMAR1 | |
| SCHEMBL3063295 | 0.65 | CHRM3 (0.59) | DRD2DRD4DRD3ACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1847530-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | ARG1, PRMT5, PRMT1 | DRD2 83/4885DRD4 75/4885DRD3 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.